TCR2 THERAPEUTICS INC's ticker is TCRR and the CUSIP is 87808K106. A total of 58 filers reported holding TCR2 THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $101,463 | +48.9% | 67,642 | -0.9% | 0.03% | -56.1% |
Q4 2022 | $68,148 | -45.5% | 68,230 | -2.1% | 0.07% | -42.6% |
Q3 2022 | $125,000 | -33.2% | 69,683 | +8.3% | 0.12% | -19.0% |
Q2 2022 | $187,000 | +0.5% | 64,341 | -4.8% | 0.14% | +61.4% |
Q1 2022 | $186,000 | -52.3% | 67,563 | -19.2% | 0.09% | -38.0% |
Q4 2021 | $390,000 | – | 83,619 | – | 0.14% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
MPM BioImpact LLC | 6,741,964 | $208,528,000 | 18.01% |
MPM ASSET MANAGEMENT LLC | 4,050,865 | $125,293,000 | 17.73% |
Consonance Capital Management LP | 584,885 | $71,268,000 | 6.66% |
SILVERARC CAPITAL MANAGEMENT, LLC | 136,000 | $4,206,000 | 2.44% |
Redmile Group, LLC | 2,832,888 | $87,621,000 | 1.06% |
Altium Capital Management LP | 73,991 | $2,289,000 | 0.86% |
PFM Health Sciences, LP | 775,794 | $23,995,000 | 0.84% |
Soleus Capital Management, L.P. | 199,867 | $6,182,000 | 0.82% |
MOODY ALDRICH PARTNERS LLC | 123,639 | $3,824,000 | 0.62% |
Sofinnova Investments, Inc. | 333,707 | $10,322,000 | 0.61% |